Sarepta Therapeutics reported $115.58M in EBIT for its fiscal quarter ending in June of 2025.


Ebit Change Date
Acadia Pharmaceuticals USD 32.37M 13.08M Jun/2025
Agios Pharmaceuticals USD -127056000 20.43M Jun/2025
Alnylam Pharmaceuticals USD 4.89M 13.19M Jun/2025
Amgen USD 2.26B 1.34B Jun/2025
Biogen USD 816.6M 233.8M Jun/2025
BioMarin Pharmaceutical USD 276.89M 52.99M Jun/2025
Daiichi Sankyo JPY 96.71B 69.64B Jun/2025
Eli Lilly USD 7.02B 3.32B Jun/2025
Gilead Sciences USD 2.7B 189M Jun/2025
Incyte USD 310.82M 27.18M Jun/2025
Insmed USD -253876000 5.74M Jun/2025
Ionis Pharmaceuticals USD 144.78M 290.78M Jun/2025
Moderna USD -817000000 146M Jun/2025
Neurocrine Biosciences USD 145.6M 121.9M Jun/2025
Pfizer USD 2.6B 3.33B Jun/2025
PTC Therapeutics USD -34858000 1.01B Jun/2025
Regeneron Pharmaceuticals USD 1.52B 608.6M Jun/2025
Roche Holding CHF 11.29B 2.68B Jun/2024
Sanofi EUR 1.51B 1.39B Jun/2025
Sarepta Therapeutics USD 115.58M 415.96M Jun/2025
Tectonic Therapeutic USD -22332000 8.34M Jun/2025
Ultragenyx Pharmaceutical USD -193567000 50.63M Jun/2025
Vertex Pharmaceuticals USD 1.15B 420.8M Jun/2025